CTOs on the Move

F H Ayer Manufacturing Company

www.fhayer.com

 
F H Ayer Manufacturing Company is a Chicago Heights, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.fhayer.com
  • 2015 S Halsted St
    Chicago Heights, IL USA 60411
  • Phone: 708.755.0550

Executives

Name Title Contact Details

Similar Companies

Envision Wellness

Envision Wellness WNY Behavioral Health has been providing counseling and treatment services in WNY for decades to all persons who have requested guidance.

ErgoSuture

Ergosuture - wound closure, enhanced suturing devices

Greater Chattanooga Orthodontics

Let us help make your smile beautiful TODAY! At Greater Chattanooga Orthodontics our commitment to excellence is apparent in all that we do. Our friendly staff can help develop a personalized plan for your specific orthodontic needs. Call TODAY to ...

Janssen

Janssen, a pharmaceutical company of Johnson & Johnson, has been an innovator in the Canadian healthcare industry for over 50 years. We are guided by Our Credo, where our first responsibility is to the doctors, nurses and patients, and mothers and fathers, and all others who use our products and services. Our ultimate goal is to help people live healthy lives.

Immunic

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn`s disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.